ROP Stock Analysis: Roche Holding | SW
Drug Manufacturers - General | SW, Switzerland | Market Cap: 276.637m CHF | 12M Return: 25.6% | CH1499059983 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 328M
Rev. Trend: 59.3%
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Roche Holding AG is a Swiss multinational healthcare company operating two core divisions: pharmaceuticals and diagnostics. Its pharmaceutical business spans a broad range of therapeutic areas, including oncology (blood and solid tumors), dermatology, haematology, infectious diseases, inflammatory and autoimmune conditions, neurology, ophthalmology, respiratory disorders, and transplantation. The diagnostics division provides in vitro tests for diseases such as cancer, diabetes, Covid-19, and hepatitis, along with diagnostic instruments and digital health solutions. The company maintains a global footprint across Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand, and is headquartered in Basel, Switzerland, where it was founded in 1896.
Roche is notable for combining a major pharmaceutical business with a leading diagnostics operation under one corporate structure, a dual model that is relatively uncommon among large pharmaceutical peers and supports integration between drug development and companion diagnostics. The company also pursues external innovation through partnerships, such as its collaboration with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors, reflecting ongoing investment in targeted oncology therapies.
- Vabysmo and Hemlibra sales offset biosimilar erosion in oncology
- Diagnostics revenue declines as COVID testing demand normalizes
- Carmot acquisition expands pipeline into obesity and diabetes therapeutics
| Net Income: 12.3b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.75 > 1.0 |
| NWC/Revenue: 10.81% < 20% (prev 12.98%; Δ -2.16% < -1%) |
| CFO/TA 0.19 > 3% & CFO 18.4b > Net Income 12.3b |
| Net Debt (23.6b) to EBITDA (22.8b): 1.03 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (809.3m) vs 12m ago 0.65% < -2% |
| Gross Margin: 73.32% > 18% (prev 73.13%; Δ 0.19% > 0.5%) |
| Asset Turnover: 63.16% > 50% (prev 66.04%; Δ -2.88% > 0%) |
| Interest Coverage Ratio: 14.07 > 6 (EBIT TTM 19.5b / Interest Expense TTM 1.38b) |
| A: 0.07 (Total Current Assets 35.4b - Total Current Liabilities 28.8b) / Total Assets 98.2b |
| B: 0.48 (Retained Earnings 47.5b / Total Assets 98.2b) |
| C: 0.20 (EBIT TTM 19.5b / Avg Total Assets 96.5b) |
| D: 0.53 (Book Value of Equity 32.7b / Total Liabilities 61.5b) |
| Altman-Z'' = 3.93 = AA |
| DSRI: 1.11 (Receivables 13.3b/12.4b, Revenue 60.9b/62.6b) |
| GMI: 1.00 (GM 73.13% / 73.32%) |
| AQI: 1.05 (AQ_t 0.40 / AQ_t-1 0.38) |
| SGI: 0.97 (Revenue 60.9b / 62.6b) |
| TATA: -0.06 (NI 12.3b - CFO 18.4b) / TA 98.2b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at CHF 357.80 with a total of 441,064 shares traded. Over the past week, the price has changed by +3.50%, over one month by +2.90%, over three months by +6.65% and over the past year by +25.60%.
Current recommended Stop Loss: 335.90 (which is 6.1% or 2.7 ATR below the current price).
Roche Holding has no consensus analysts rating.
P/E Trailing = 22.6632
P/E Forward = 16.5017
P/S = 4.3939
P/B = 8.8516
P/EG = 1.6585
Revenue TTM = 60.9b CHF
EBIT TTM = 19.5b CHF
EBITDA TTM = 22.8b CHF
Long Term Debt = 25.2b CHF (from longTermDebt, last quarter)
Short Term Debt = 6.58b CHF (from shortTermDebt, last quarter)
Debt = 33.4b CHF (from shortLongTermDebtTotal, last quarter) + Leases 1.55b
Net Debt = 23.6b CHF (calculated: Debt 33.4b - CCE 9.73b)
Enterprise Value = 300b CHF (277b + Debt 33.4b - CCE 9.73b)
Interest Coverage Ratio = 14.07 (Ebit TTM 19.5b / Interest Expense TTM 1.38b)
EV/FCF = 20.34x (Enterprise Value 300b / FCF TTM 14.8b)
FCF Yield = 4.92% (FCF TTM 14.8b / Enterprise Value 300b)
FCF Margin = 24.23% (FCF TTM 14.8b / Revenue TTM 60.9b)
Net Margin = 20.25% (Net Income TTM 12.3b / Revenue TTM 60.9b)
Gross Margin = 73.32% ((Revenue TTM 60.9b - Cost of Revenue TTM 16.3b) / Revenue TTM)
Gross Margin QoQ = 73.72% (prev 72.93%)
Tobins Q-Ratio = 3.06 (Enterprise Value 300b / Total Assets 98.2b)
Interest Expense / Debt = 4.15% (Interest Expense 1.38b / Debt 33.4b)
Taxrate = 18.74% (3.07b / 16.4b)
NOPAT = 15.8b (EBIT 19.5b * (1 - 18.74%))
Current Ratio = 1.23 (Total Current Assets 35.4b / Total Current Liabilities 28.8b)
Debt / Equity = 1.02 (Debt 33.4b / totalStockholderEquity, last quarter 32.7b)
Debt / EBITDA = 1.03 (Net Debt 23.6b / EBITDA 22.8b)
Debt / FCF = 1.60 (Net Debt 23.6b / FCF TTM 14.8b)
Total Stockholder Equity = 31.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.79% (Net Income 12.3b / Total Assets 98.2b)
RoE = 38.89% (Net Income TTM 12.3b / Total Stockholder Equity 31.7b)
RoCE = 34.15% (EBIT 19.5b / Capital Employed (Equity 31.7b + L.T.Debt 25.2b))
RoIC = 21.69% (NOPAT 15.8b / Invested Capital 72.9b)
WACC = 5.31% (E(277b)/V(310b) * Re(5.54%) + D(33.4b)/V(310b) * Rd(4.15%) * (1-Tc(0.19)))
Discount Rate = 5.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -50.34 | Cagr: -2.54%
[DCF] Terminal Value 77.97% ; FCFF base≈13.9b ; Y1≈15.9b ; Y5≈23.4b
[DCF] Fair Price = 476.9 (EV 353b - Net Debt 23.6b = Equity 329b / Shares 690.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 59.26 | Revenue CAGR: 1.61% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=20.34 | Chg30d=-0.04% | Revisions=+12% | GrowthEPS=+4.5% | GrowthRev=+1.9%
EPS next Year (2027-12-31): EPS=21.91 | Chg30d=+0.03% | Revisions=+35% | GrowthEPS=+7.7% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +26% (up=18, down=10)